Ikonisys and Hospitex International Win Major Public Tender
In a significant advancement for cancer diagnostics, Ikonisys SA (Euronext Growth Paris: ALIKO) has announced that its fully-owned subsidiary, Hospitex International, has successfully secured a major public tender for the supply of diagnostic systems to a prestigious medical unit. This achievement underscores Hospitex’s commitment to innovation that enhances cancer detection methods.
Contribution to the U.O.C. Pathological Anatomy Unit
The tender awarded to Hospitex includes a full in-service supply of the CYTOfast system, valued at nearly €400,000. This agreement aims to improve diagnostic processes within the U.O.C. Pathological Anatomy Unit. The project was initiated to cater to the essential needs of the Public Health Laboratory Unit, demonstrating the growing demand for advanced diagnostic solutions.
Assessment Process and Compliance
During the public session for the tender, a detailed evaluation was conducted by a commission reviewing the administrative and technical documentation of attending companies. This rigorous process reflects the stringent standards required in the healthcare sector, where precision and reliability in diagnostics are paramount.
Francesco Trisolini's Vision for the Future
Francesco Trisolini, COO of Ikonisys and CEO of Hospitex, expressed enthusiasm about this achievement, stating that it is a significant milestone affirming their dedication to advancing diagnostic accuracy. This victory paves the way for future projects where Ikonisys aims to solidify its leadership role in the cancer diagnostics sector.
Strategic Impact on Ikonisys Group
Winning this public tender is not merely a contract; it represents an opportunity for Ikonisys Group to engage in key healthcare projects that can reshape diagnostic practices. The confidence placed in Hospitex reflects their innovative solutions and the essential role they play in the evolving field of pathology.
Hospitex International: A Leader in Cytology
Recognized globally, Hospitex International specializes in cytology standardized monolayer preparations. Their advanced CYTOfast system has transformed cytological diagnostics by offering a comprehensive suite of integrated solutions that streamline diagnostic processes and improve operational efficiency. In a time when there is a global shortage of pathology expertise, companies like Hospitex are stepping up to provide essential tools that ensure diagnostic safety and effectiveness.
About Ikonisys and Its Innovations
Ikonisys operates on the forefront of cell-based diagnostics, employing cutting-edge technology to enhance the precision of cancer detection. With operations in major cities such as Paris, New Haven, and Milan, the company has developed the proprietary Ikoniscope20 and Ikoniscope20max platforms. These fully automated solutions are designed to accurately analyze rare and critically significant cells, demonstrating Ikonisys' commitment to high-quality diagnostic practices.
Furthermore, Ikonisys has garnered FDA clearance for numerous automated diagnostic applications, which also comply with European CE standards. Ongoing developments include innovative tests, such as liquid biopsy tests that utilize Circulating Tumor Cells (CTC), showcasing the company's dedication to advancing oncological diagnostics.
Frequently Asked Questions
What is the significance of the tender won by Ikonisys?
The tender allows Ikonisys, through Hospitex, to supply important diagnostic systems that enhance cancer diagnosis efficiency.
What technology does Hospitex’s CYTOfast system utilize?
CYTOfast uses advanced automation for cytology diagnostics, streamlining workflows in pathology labs.
How does Ikonisys contribute to cancer diagnostics?
Ikonisys provides innovative, automated solutions for detecting rare cells, which is crucial for timely cancer diagnosis.
Where are Ikonisys and Hospitex International located?
Ikonisys operates in Paris, New Haven, and Milan, providing services globally through its subsidiaries.
What future projects might Ikonisys pursue after this tender?
Winning this tender positions Ikonisys to engage in major healthcare projects that could further advance diagnostic technologies.
